Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Transcatheter mitral valve repair for patients with HF and severe secondary mitral regurgitation ...
Abbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial for MitraClip, demonstrating the long-term benefits of the device in patients fighting heart failure.
NEW ORLEANS — To much acclaim, the COAPT trial demonstrated that use of the MitraClip (Abbott) in a very sick population with symptomatic (heart failure (HF) and secondary mitral regurgitation (MR) ...
New five-year data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal of Medicine reinforce the long-term safety and ...
BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...
Abbott: Data Show Long-Term Benefits Of MitraClip Device For Treating Secondary Mitral Regurgitation
(RTTNews) - Abbott (ABT) said new five-year data from Landmark COAPT trial reinforced the long-term safety and effectiveness of MitraClip device for treating secondary mitral regurgitation. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results